SBC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SBC Medical Group Holdings Inc is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company shows some positive growth prospects, the technical indicators are bearish, and the stock lacks immediate upward momentum. It is better to wait for clearer signs of growth or a stronger technical setup before investing.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 46.787, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.676, with key support at 3.52 and resistance at 3.833.
The company is expanding its operations with the launch of the flagship 'NEO Skin Clinic' in Tokyo's Ginza district, targeting high-end clients and leveraging advanced diagnostic systems. Plans to expand into Nagoya and Kobe by the end of 2026 indicate a focus on sustainable growth. Analyst coverage initiated with a Buy rating and an $8 price target highlights potential growth opportunities.
The company's revenue dropped by 18.33% YoY in Q3 2025, and gross margin decreased by 13.31% YoY, indicating challenges in operational efficiency. Technical indicators are bearish, and the stock has a 60% chance of declining in the short term. No significant hedge fund or insider trading activity suggests a lack of strong institutional confidence.
In Q3 2025, SBC's revenue dropped by 18.33% YoY to $43,353,235. However, net income increased significantly by 352.70% YoY to $12,824,636, and EPS rose by 300% YoY to 0.12. Gross margin declined to 70.61%, down 13.31% YoY, indicating a mixed financial performance with profitability improvements but declining revenue and margins.
BTIG analyst Sam Eiber initiated coverage with a Buy rating and an $8 price target, citing SBC's leadership in the aesthetic medical market in Japan, numerous growth prospects, and valuation discount compared to peers.
